Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics ...
Mar 18, 2024 · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”).
BMS wins approval for schizophrenia drug acquired from Karuna
Sep 27, 2024 · However, in a Q1 2023 earnings call, Karuna’s former CEO Bill Meury suggested that adherence to Cobenfy could surpass standard schizophrenia treatments. To tackle this issue, Terran Biosciences are developing a prodrug version of xanomeline-trospium, called TerXT.
First new type of treatment for schizophrenia in decades - NPR
Sep 27, 2024 · For the first time in decades, the Food and Drug Administration has approved a new type of drug for schizophrenia. The twice-a-day pill to be marketed by Bristol Myers Squibb will be called...
F.D.A. Approves a New Antipsychotic Drug - The New York Times
Sep 26, 2024 · In its submission of the drug for F.D.A. approval, Karuna cited a five-week study of 252 people with schizophrenia, half of whom were given Cobenfy and the other half, a placebo. The results...
FDA approves first schizophrenia drug with new mechanism of …
Sep 26, 2024 · The FDA has approved Karuna/Bristol Myers Squibb’s KarXT (Cobenfy) — an oral dual M1/M4 muscarinic acetylcholine receptor (mAChR) agonist — for schizophrenia.
Approval in hand, Bristol Myers sets out to sell first-of-its-kind ...
Sep 26, 2024 · The medicine, which will be sold as Cobenfy, was developed by Boston-based biotechnology company Karuna Therapeutics. In three medium-to large-sized clinical trials, Karuna showed that treatment with Cobenfy significantly relieved schizophrenia symptoms in people with the mental disorder.
Bristol Myers Squibb's Karuna buyout pays off with FDA approval …
Sep 26, 2024 · BMS’ first-in-class drug KarXT—now dubbed Cobenfy—won a landmark FDA approval Thursday to treat adults with schizophrenia. The medicine represents the first antipsychotic that targets...
BMS achieves FDA approval for schizophrenia drug Cobenfy
Oct 1, 2024 · Cobenfy (KarXT) is the first completely new type of schizophrenia drug to be approved for more than 30 years. Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in …
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers …
Sep 27, 2024 · On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE: BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the...
FDA approves schizophrenia drug that could alter how disorder is …
Sep 26, 2024 · On Thursday, the Food and Drug Administration approved for the first time a new type of medicine that may change the way the psychiatric disorder is treated. The drug, called Cobenfy, will be...